文献速递免疫规划传染病防控与疫情报告

罗马尼亚医护人员队列中BNT162b2疫苗诱导的强结合SARS-CoV-2 IgG抗体的纵向测定

Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers.
PubMed 文献 · Vaccine · 2022-08-01

该研究对166名接种BNT162b2的罗马尼亚医护人员进行纵向随访,使用内部开发的IgG ELISA检测1694份样本。既往感染组IgG水平在六个月内持续高于未感染组,且加强针在未感染组中诱导的IgG中位数高于第二剂后水平,在既往感染组中则与第二剂后水平相当。

要点

  • 既往感染组接种后两周达IgG峰值,未感染组在第二剂后骤升。
  • 六个月内既往感染组IgG中位数持续高于未感染组。
  • 加强针在未感染组诱导的IgG中位数高于第二剂后水平。

核心结论

  • 接种BNT162b2后,既往感染者的IgG水平快速达峰并维持更高水平,未感染者IgG逐渐升高且在第二剂后骤增;加强针可提升未感染者的IgG水平。

研究设计与样本

  • 纵向分析166名接种BNT162b2的罗马尼亚医护人员,第一剂后每周随访至35天,每月随访至6个月,部分参与者6个月后继续随访并接种加强针或感染。

主要发现

  • 第一剂后36-65天,既往感染组IgG中位数为5.29 AU/ml,未感染组为3.58 AU/ml,p小于0.001。
  • 接种后7-8个月,未感染组IgG中位数为0.7 AU/ml,既往感染组为1.29 AU/ml,p=0.006。
  • 加强针后,未感染组IgG中位数高于第二剂后水平,既往感染组与第二剂后水平相当。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mass vaccination against the disease caused by the novel coronavirus (COVID-19) was a crucial step in slowing the spread of SARS-CoV-2 in 2021. Even in the face of new variants, it still remains extremely important for reducing hospitalizations and COVID-19 deaths. In order to better understand the short- and long-term dynamics of humoral immune response, we present a longitudinal analysis of post-vaccination IgG levels in a cohort of 166 Romanian healthcare workers vaccinated with BNT162b2 with weekly follow-up until 35 days past the first dose and monthly follow-up up to 6 months post-vaccination. A subset of the patients continued with follow-up after 6 months and either received a booster dose or got infected during the Delta wave in Romania. Tests were carried out on 1694 samples using a CE-marked IgG ELISA assay developed in-house, containing S1 and N antigens of the wild type virus. Participants infected with SARS-CoV-2 before vaccination mount a quick immune response, reaching peak IgG levels two weeks after the first dose, while IgG levels of previously uninfected participants mount gradually, increasing abruptly after the second dose. Overall higher IgG levels are maintained for the previously infected group throughout the six month primary observation period (e.g. 36-65 days after the first dose, the median value in the previously infected group is 5.29 AU/ml, versus 3.58 AU/ml in the infection naïve group, p less than 0.001). The decrease of IgG levels is gradual, with lower median values in the infection naïve cohort even 7-8 months after vaccination, compared to the previously infected cohort (0.7 AU/ml versus 1.29 AU/ml, p = 0.006). Administration of a booster dose yielded higher median IgG antibody levels than post second dose in the infection naïve group and comparable levels in the previously infected group.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Korodi M, Horváth I, Rákosi K, et al. Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers. Vaccine. 2022. PMID: 35931634. doi:10.1016/j.vaccine.2022.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。